Just caring: Assessing the ethical and economic costs of personalized medicine

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 202-206

  Fleck, Leonard M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cancer drugs; Cost effectiveness; Health care justice; Health care rationing; Personalized medicine; Rational democratic deliberation

Indexed keywords

BEVACIZUMAB; DASATINIB; IMATINIB; NILOTINIB; PACLITAXEL;

CANCER RESEARCH; CANCER THERAPY; CARE AND CARING; ETHICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MORALITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW;

CANCER DRUGS; COST-EFFECTIVENESS; HEALTH CARE JUSTICE; HEALTH CARE RATIONING; PERSONALIZED MEDICINE; RATIONAL DEMOCRATIC DELIBERATION;

DELIVERY OF HEALTH CARE; EMPATHY; HEALTH CARE COSTS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84892528364     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.013     Document Type: Review

References (24)

1. Personalized Medicine Coalition. The case for personalized medicine. 3rd ed. 〈〉 [accessed 19.07.13]. http://www.personalizedmedicinecoalition.org/about/about-personalized-medicine/the-case-for-personalized-medicine.
2. Gazdar A.F., Minna J.D. Precision medicine for cancer patients: lessons learned and the path forward. J Natl Cancer Inst 2013, 105:1262-1263.
3. Fleck L.M. Just caring: health care rationing and democratic deliberation 2009, Oxford University Press, New York.
4. Fleck L.M. Just caring: health care rationing, terminal illness, and the medically least well off. J Law Med Ethics 2011, 39:156-171.
5. Fleck L.M. Just caring: defining a basic benefit package. J Med Philos 2011, 36:589-611.
6. Fleck L.M. Pharmacogenomics and personalized medicine: wicked problems, ragged edges, and ethical precipices. New Biotechnol 2012, 29:757-768.
7. Callahan D. What kind of life: the limits of medical progress 1990, Simon and Schuster, New York.
8. Keehan S.P., Sisko A.M., Truffer C.J., et al. National health spending projections through 2020: economic recovery and reform drive faster spending growth. Health Aff 2011, 30:1594-1605.
9. The price of drugs for chronic myeloid leukemia [CML] is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442. Experts in Chronic Myeloid Leukemia.
10. Fojo T., Grady C. How much is life worth: non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
11. Fojo T., Parkinson D.R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. Clin Cancer Res 2010, 16:5972-5980.
12. Fleck L.M. Last chance therapies: can a just and caring society do health care rationing when life itself is at stake?. Yale J Health Policy Law Ethics 2002, 2:255-298.
13. Hess G., Borker R., Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer 2013, 11:161-167.
14. Roychowdhury S., Chinnaiyan A.M. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013, 31:1866-1873.
15. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
16. Gonzalez de Castro D., Clarke P.A., Al-Lazikani B., Workman P. Personalized cancer medicine: molecular diagnostics, positive biomarkers, and drug resistance. Clin Pharmacol Ther 2013, 93:252-259.
17. Garraway L.A., Janne P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012, 2:214-226.
18. Jabbour E.J., Cortes J.E., Kantarjian H.M. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 2013, 13:515-529.
19. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
20. Raspe E., Decraene C., Berx G. Gene expression profiling to dissect the complexity of cancer biology: pitfalls and promise. Semin Cancer Biol 2012, 22:250-260.
21. Longo D.L. Tumor heterogeneity and personalized medicine. N Engl J Med 2012, 366:956-957.
22. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012, 30:679-692.
23. Yap T.A., Omlin A., de Bono J.S. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013, 31:1592-1605.
24. Garraway L.A. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013, 31:1806-1814.